ArticleJAMA oncology2026

Long-Term Outcomes in Patients With Recurrent Ovarian Cancer and Exceptional Response to PARP Inhibitors.

Lucy Haggstrom et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.